Skip to Content

Generic Dilaudid-HP Availability

See also: Generic Dilaudid

Dilaudid-HP is a brand name of hydromorphone, approved by the FDA in the following formulation(s):

DILAUDID-HP (hydromorphone hydrochloride - injectable;injection)

  • Manufacturer: FRESENIUS KABI USA
    Approval date: January 11, 1984
    Strength(s): 10MG/ML [RLD] [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: August 4, 1994
    Strength(s): 250MG/VIAL

Has a generic version of Dilaudid-HP been approved?

A generic version of Dilaudid-HP has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Dilaudid-HP and have been approved by the FDA:

hydromorphone hydrochloride injectable;injection

  • Manufacturer: AKORN
    Approval date: April 14, 2010
    Strength(s): 10MG/ML [AP], 10MG/ML [AP]
  • Manufacturer: BARR
    Approval date: April 25, 2003
    Strength(s): 10MG/ML [AP]
  • Manufacturer: HOSPIRA INC
    Approval date: June 17, 2008
    Strength(s): 10MG/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilaudid-HP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Hydromorphone and hydrocodone compositions and methods for their synthesis
    Patent 6,589,960
    Issued: July 8, 2003
    Inventor(s): William H.; Harclerode & Robert; Gault & Mark D.; Sandison
    Assignee(s): Abbott Laboratories
    A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
    Patent expiration dates:
    • November 9, 2020
      Drug product
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.